KOALA
IB Lab GmbH • Radiology • 11/05/2019
Device Purpose
The KOALA software is an automated image processing system that utilizes machine learning algorithms to analyze CR or DX knee radiographs for signs of osteoarthritis by measuring joint space width and detecting features based on OARSI and Kellgren-Lawrence criteria. Its purpose is to provide quantitative and qualitative data to aid trained medical professionals in the assessment and grading of knee OA, supported by clinical validation demonstrating its accuracy in feature detection and measurement.
Summary
IB Lab's KOALA is a fully-automated radiological image processing software designed to assist medical professionals in evaluating knee osteoarthritis (OA) from computed (CR) or directly digital (DX) X-ray images. It employs computer vision and machine learning algorithms to analyze posterior-anterior or anterior-posterior knee radiographs of adult patients. The software provides quantitative measurements of minimum joint space width and indicators for the presence or absence of key radiographic OA features, including sclerosis, joint space narrowing, and osteophytes, based on OARSI criteria, as well as an assessment of radiographic knee OA according to Kellgren & Lawrence Grading. These outputs are compiled into a KOALA report, accessible via any DICOM viewer workstation, and are intended for use by trained professionals such as radiologists, orthopedists, physicians, and medical technicians, though not as a sole basis for diagnosis. The performance of KOALA was validated using a substantial dataset of 6597 radiographs from 1149 individuals in the Osteoarthritis Initiative (OAI) study, with ground truth established by three physicians. For OA feature detection, KOALA demonstrated sensitivities and specificities as follows: Kellgren-Lawrence status (KL ≥ 2) showed 0.87 sensitivity and 0.83 specificity; joint space narrowing (OARSI > 0) had 0.83 sensitivity and 0.80 specificity; osteophytosis (OARSI > 0) achieved 0.86 sensitivity and 0.79 specificity; and sclerosis (OARSI > 0) resulted in 0.82 sensitivity and 0.80 specificity. Furthermore, joint space width (JSW) measurements showed good agreement with reference measurements from the OAI study, with orthogonal linear regression yielding a slope of 1.02 and intercept of -0.08 mm for medial JSW, and a slope of 0.97 and intercept of 0.08 mm for lateral JSW, supporting the device's reliability.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does KOALA's performance in detecting early-stage osteoarthritis compare to its performance in more advanced stages, and are there specific thresholds for OARSI or Kellgren-Lawrence grades where its accuracy is maximized?; What impact does variability in X-ray acquisition parameters (e.g., beam angle, patient positioning consistency for fixed-flexion views) have on the robustness and reliability of KOALA's joint space width measurements and feature detection?; Could the KOALA software be adapted or expanded to analyze longitudinal changes in knee OA progression in individual patients over time, potentially serving as a tool for monitoring treatment efficacy?; What were the specific adjudication procedures used by the three physicians to establish ground truth for the OAI dataset, and how was inter-observer variability among them managed before creating the reference standard?; Beyond the reported sensitivity and specificity, what are the positive predictive value (PPV) and negative predictive value (NPV) of KOALA's indicators in a typical clinical population with varying OA prevalence?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly